Analyst: Joseph Pantginis, Ph.D.

Analyst

Dr. Joseph Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.

Continue reading “Analyst: Joseph Pantginis, Ph.D.”

Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

Article - Media

H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

Ryan Adist

SmarterAnalyst, 30 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Article - Media

H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Article - Media

H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Christine Brown

SmarterAnalyst, 29 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED: